

Patent Information Initiative for Medicines Pat-INFORMED

December 3, 2018

Thomas Bombelles

Head, NGO and Industry Relations







What is Pat-INFORMED?

- The **Pat**ent **Information In**itiative **for Med**icines, (Pat-INFORMED) is a search engine to help pharmaceutical procurement agencies determine the patent status of a medicine.
- It facilitates access to and availability of pharmaceutical patent information to inform procurement decisions.
- Pat-INFORMED is a partnership among WIPO, IFPMA and 20 global pharma companies.





Why create Pat-INFORMED?

- Greater transparency of patent information on medicines.
- "WIPO Development Agenda Goal 31:"... Better access to publicly available patent information...
- UN Sustainable Development Goals:
 - Goal 3. Promote health and well-being
 - Goal 9. Foster innovation
 - Goal 17. Strengthen implementation through partnerships





Which therapeutic areas does Pat-INFORMED cover?

HIV/ AIDS

Cardiovascular diseases

Diabetes

Hepatitis C

Oncology

Respiratory conditions



All products on the WHO EML that are not within these therapy areas

→ After the launch, the database will begin to be expanded to other therapeutic areas.





Who can use Pat-INFORMED?



 Pat-INFORMED is accessible to everybody, but it is specifically aimed at pharmaceutical procurement services and related specialists of:



- International bodies and donors
- National pharmaceutical services
- · Ministries of health
- National patent offices





PAT-INFORMED

Patent Information Initiative for Medicines



PAT-INFORMED



My account | Terms of use | Contact us Hosted by WIPO Search pharmaceutical patents by INN - Ex : erlotinib hydrochloride Q Country -Display all INNs INN Participant **Patents** Fluticasone Propionate, AEROSOL CONTAINER FOR FORMULATIONS OF SALMETEROL XINAFOATE Salmeterol Xinafoate CALCIUM (3S) TETRAHYDRO-3-FURANYL(1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO] -1-BENZYL-2- (PHOSPHONOOXY) PROPYLCARBAMATE Fosamprenavir Calcium Bristol-Myers Squibb FORMULATIONS OF A SRC/ABL INHIBITOR Dasatinib STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-Roche Erlotinib Hydrochloride QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF Roche Vemurafenib COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION Lenvatinib Mesilate Azilsartan Medoxomil, Takeda SOLID PHARMACEUTICAL COMPOSITION Chlortalidone **astellas Enzalutamide Treatment Of Hyperproliferative Disorders With Diarylhydantoin Compounds Bristol-Myers Squibb Efavirenz CRYSTALLINE EFAVIRENZ Umeclidinium Bromide, PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES Vilanterol Trifenatate Fluticasone Furoate COUNTER FOR USE WITH A MEDICAMENT DISPENSER CARBOCYCLIC NUCLEOSIDE HEMISULFATE AND ITS USE IN TREATING VIRAL Abacavir Sulfate POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY



PAT-INFORMED










PAT-INFORMED

Patent Information Initiative for Medicines









Thank you

For further information contact:

Thomas Bombelles

- +41 22 338 82 96
- thomas.bombelles@wipo.int



Guilherme Cintra

- +41 22 338 32 22
- g.cintra@ifpma.org



